Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
222 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT07164794 | Memantine Hydrochloride in Prostate Cancer Patients | not yet recruiting | Phase 2 | 15 | Bin XuOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07172126 |
| Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets |
| not yet recruiting |
| Phase 1 / Phase 2 |
| 291 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| Sep 15, 2025 |
| clinicaltrials |
| NCT06134232 | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T(ProvONE) | recruiting | Phase 2 | 400 | DendreonINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06241846 | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04015622 | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA(PROTRACT) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06972628 | Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | recruiting | Phase 2 | 30 | Ebrahim S DelpassandOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06971211 | Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC(PARTOM) | recruiting | Phase 2 | 40 | Jianbin BiOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06890832 | A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | not yet recruiting | Phase 2 | 75 | Jina Pharmaceuticals Inc.INDUSTRY | 0 | Mar 24, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03230734 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer(RAPSON) | active not recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2025source: clinicaltrials